Radiotherapy after subtotally resected or recurrent ganglioglioma

Liauw, Stanley L.; Byer, Jennifer; Yachnis, Anthony T.; Amdur, Robert J.; Mendenhall, William M.

doi:10.1016/j.ijrobp.2006.08.029

Cited by 44 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant radiotherapy is indicated for patients with anaplasia. 19 However, patients with subtotal resections but low-grade histologies should be observed initially for disease progression since the recurrence rate for this cohort may be as low as 15% while radiotherapy may predispose to malignant degeneration of the tumour. 17,20 Complete resection of supratentorial gangliogliomas as defined by post-operative MRI is associated with a significantly reduced risk of tumour recurrence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pontomedullary ganglioglioma: A rare tumour in an unusual location

Westwood

MacFarlane

2009

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…17 If the disease recurs or progresses, then salvage radiotherapy may be indicated. 19 However, in children the detrimental effects of intracranial irradiation on intellectual and endocrine development should be taken into account. Chemotherapy is not beneficial.…”

Section: Discussionmentioning

confidence: 99%

Pontomedullary ganglioglioma: A rare tumour in an unusual location

Westwood

MacFarlane

2009

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…The treatment of choice is surgical resection, but only complete resection results in long-term, disease-free survival [33] [34]. GGs displaying malignant features may benefit from RT while the efficacy of chemotherapy is unknown [35].…”

Section: Discussionmentioning

confidence: 99%

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10)

Burzynski¹,

Janicki²,

Burzynski³

et al. 2017

JCT

View full text Add to dashboard Cite

Despite dramatic progress over the last 50 years in the treatment of many childhood cancers, primary brain tumors remain the leading cause of death in pediatric oncology. This phase II study evaluated the efficacy and safety of Antineoplastons A10 and AS2-1 given in combination (ANP). Thirty-four patients, with a median age of 10.4 years, were enrolled in the study. Thirty-two patients (94.1%), were Caucasians while 21 (61.8%) were female and 13 were male (38.2%). Twenty-four patients (70.6%) suffered from a brainstem glioma (BSG) or high-grade tumor. Ten patients (29.4%) suffered from a low-grade tumor. A distinct sub-group of three patients with low grade tumors had a ganglioglioma (GG). Eighty-two percent of patients had failed standard treatment. Daily ANP was administered by IV infusion, every four hours, until an objective response (OR) was documented, and then for an additional eight months. The median doses of A10 and AS2-1 were 11.64 g/kg/d and 0.45 g/kg/d, respectively. A complete response (CR) was documented in two patients (5.9%), a partial response (PR) in four patients (11.8%), and stable disease (SD) in six patients (17.6%). Objective responses were observed in diffuse intrinsic pontine glioma (DIPG), thalamic pilocytic astrocytoma with brainstem involvement, ganglioglioma and pilocytic astrocytoma. Six-month progression-free survival (PFS) was 35.3%. Overall survival (OS) at two and five years was 37.6% and 34.5%, respectively. Two patients experienced grade 4 hypernatremia while three experienced grade 3 hypokalemia. In this group of patients, ANP showed good efficacy and an acceptable toxicity profile.

show abstract

“…Since the malignant degeneration has been described both in previously irradiated [14,17] and nonirradiated patients [11,18,19,20], the evidence for a relationship between RT and anaplastic transformation seems to be weak [21]. …”

Section: Discussionmentioning

confidence: 99%

“…In contrast to low-grade GG, RT is warranted also in case of gross total removal [5,21]. DeMarchi et al [5] pointed out that the outcome of patients treated with surgery only is much worse than for low-grade GGs.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature

et al. 2012

View full text Add to dashboard Cite

Gangliogliomas with anaplastic features are classified as grade III tumors by the World Health Organization. The clinical course and optimal treatment of anaplastic gangliogliomas have not been well understood to date. We report a case of a primary pure anaplastic ganglioglioma in a 14-year-old male treated with surgery and radiotherapy, who is disease-free 6 years after the diagnosis. A review of primary pure anaplastic gangliogliomas in children (between 3 and 21 years of age) is presented. Gross total removal and focal radiotherapy with a total dose of 54 Gy are recommended. The addition of chemotherapy should be evaluated. Prospective studies are needed to identify an appropriate chemotherapy schedule and to define biological factors in order to select those patients with a poor prognosis, who are to be treated with a more aggressive therapy.

show abstract

Radiotherapy after subtotally resected or recurrent ganglioglioma

Cited by 44 publications

References 21 publications

Pontomedullary ganglioglioma: A rare tumour in an unusual location

Pontomedullary ganglioglioma: A rare tumour in an unusual location

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10)

Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature

Contact Info

Product

Resources

About